Targeted Treatment of Papillary Craniopharyngiomas Harboring BRAF V600E Mutations

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2019 Jul 18

PMID 31314136

Citations 37

Authors

Tareq A Juratli

Pamela S Jones

Nancy Wang

Megha Subramanian

Simon J B Aylwin

Yazmin Odia

Elham Rostami

Olafur Gudjonsson

Brian L Shaw

Daniel P Cahill

Evanthia Galanis

Fred G Barker 2nd

Sandro Santagata

Priscilla K Brastianos

Affiliations

Soon will be listed here.

Citing Articles

The spectrum of radiation therapy options for craniopharyngioma: a systematic review.

Harary P, Rajaram S, Hori Y, Park D, Chang S J Neurooncol. 2025; .

PMID: 40063185 DOI: 10.1007/s11060-025-05001-4.

Current clinical trials for craniopharyngiomas: what's on the horizon?.

Joshi N, Mueller S, Kline C J Neurooncol. 2025; .

PMID: 40042714 DOI: 10.1007/s11060-024-04899-6.

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.

Ainiwan Y, Li H, Zheng Y, Wei S, Peng J, Nie J Acta Neuropathol Commun. 2025; 13(1):46.

PMID: 40033395 PMC: 11874662. DOI: 10.1186/s40478-025-01972-7.

Targeted treatment for craniopharyngioma.

Stec N, Barker 2nd F, Brastianos P J Neurooncol. 2025; .

PMID: 39951179 DOI: 10.1007/s11060-025-04942-0.

Rathke cleft cyst with squamous metaplasia and activating mutations of mitogen-activated protein kinase signaling: illustrative case.

Halaoui A, Estrella M, Yan C, Goodwill V, Beaumont T J Neurosurg Case Lessons. 2025; 9(3.

PMID: 39832308 PMC: 11744688. DOI: 10.3171/CASE24657.

References

Bunin G, Surawicz T, Witman P, Preston-Martin S, Davis F, Bruner J . The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998; 89(4):547-51. DOI: 10.3171/jns.1998.89.4.0547. View

Yue Q, Yu Y, Shi Z, Wang Y, Zhu W, Du Z . Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. J Neurosurg. 2017; 129(1):27-34. DOI: 10.3171/2017.4.JNS163113. View

Brose M, Cabanillas M, Cohen E, Wirth L, Riehl T, Yue H . Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(9):1272-82. PMC: 5532535. DOI: 10.1016/S1470-2045(16)30166-8. View

Muller H . Consequences of craniopharyngioma surgery in children. J Clin Endocrinol Metab. 2011; 96(7):1981-91. DOI: 10.1210/jc.2011-0174. View

Roque A, Odia Y . BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol. 2017; 6(2):95-99. PMC: 6020871. DOI: 10.2217/cns-2016-0034. View

Lustig R, Post S, Srivannaboon K, Rose S, Danish R, Burghen G . Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab. 2003; 88(2):611-6. DOI: 10.1210/jc.2002-021180. View

Rostami E, Witt Nystrom P, Libard S, Wikstrom J, Casar-Borota O, Gudjonsson O . Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien). 2017; 159(11):2217-2221. PMC: 5636852. DOI: 10.1007/s00701-017-3311-0. View

Yamini B, Narayanan M . Craniopharyngiomas: an update. Expert Rev Anticancer Ther. 2006; 6 Suppl 9:S85-92. DOI: 10.1586/14737140.6.9s.S85. View

Schlaffer S, Buchfelder M, Stoehr R, Buslei R, Holsken A . Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma. Front Genet. 2018; 9:49. PMC: 5826961. DOI: 10.3389/fgene.2018.00049. View

10.

Smee R, Williams J, Kwok B, Teo C, Stening W . Modern radiotherapy approaches in the management of craniopharyngiomas. J Clin Neurosci. 2011; 18(5):613-7. DOI: 10.1016/j.jocn.2010.12.005. View

11.

Holsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J . Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun. 2016; 4:20. PMC: 4770705. DOI: 10.1186/s40478-016-0287-6. View

12.

Brastianos P, Shankar G, Gill C, Taylor-Weiner A, Nayyar N, Panka D . Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst. 2015; 108(2). PMC: 4862417. DOI: 10.1093/jnci/djv310. View

13.

Fujio S, Juratli T, Arita K, Hirano H, Nagano Y, Takajo T . A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. Neurosurgery. 2018; 85(2):204-210. DOI: 10.1093/neuros/nyy569. View

14.

Brastianos P, Taylor-Weiner A, Manley P, Jones R, Dias-Santagata D, Thorner A . Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014; 46(2):161-5. PMC: 3982316. DOI: 10.1038/ng.2868. View

15.

Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M . Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 1999; 90(2):237-50. DOI: 10.3171/jns.1999.90.2.0237. View

16.

Omay S, Chen Y, Almeida J, Ruiz-Trevino A, Boockvar J, Stieg P . Do craniopharyngioma molecular signatures correlate with clinical characteristics?. J Neurosurg. 2017; 128(5):1473-1478. DOI: 10.3171/2017.1.JNS162232. View

17.

Mortini P, Losa M, Pozzobon G, Barzaghi R, Riva M, Acerno S . Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. J Neurosurg. 2011; 114(5):1350-9. DOI: 10.3171/2010.11.JNS10670. View

18.

Himes B, Ruff M, Van Gompel J, Park S, Galanis E, Kaufmann T . Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg. 2018; 130(4):1299-1303. DOI: 10.3171/2017.11.JNS172373. View

19.

Aylwin S, Bodi I, Beaney R . Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary. 2015; 19(5):544-6. PMC: 4996872. DOI: 10.1007/s11102-015-0663-4. View